SCHEMBL23851693

SCHEMBL23851693

Nc1cc(C(F)(F)F)ccc1N1CC2CCC(C1)C2O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
KDM4E B2RXH2 3/20 0.54
LMNA P02545 2/20 0.54
PKM P14618 1/20 0.49
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CFTR P13569 1/20 0.38
MDM2 Q00987 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 2/20 0.37
AADAT Q8N5Z0 1/20 0.37
LIPG Q9Y5X9 4/20 0.37
NOS3 P29474 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31588198 0.85 ALDH1A1 (0.59) ALDH1A1KDM4ELMNAPKMMAPT
SCHEMBL23850602 0.85 ALDH1A1 (0.59) ALDH1A1KDM4ELMNAPKMMAPT
SCHEMBL23851407 0.81 ALDH1A1 (0.55) ALDH1A1KDM4ELMNAPKMMAPT
SCHEMBL23851405 0.81 ALDH1A1 (0.55) ALDH1A1KDM4ELMNAPKMMAPT
SCHEMBL28623162 0.80 ALDH1A1 (0.48) ALDH1A1KDM4ELMNAPKMMAPT
SCHEMBL31588171 0.80 ALDH1A1 (0.57) ALDH1A1KDM4ELMNAPKMMAPT
SCHEMBL23851040 0.80 ALDH1A1 (0.57) ALDH1A1KDM4ELMNAPKMMAPT
SCHEMBL23851042 0.80 ALDH1A1 (0.57) ALDH1A1KDM4ELMNAPKMMAPT
SCHEMBL23850440 0.78 ALDH1A1 (0.58) ALDH1A1KDM4ELMNAPKMMAPT
SCHEMBL23850683 0.78 LMNA (0.65) ALDH1A1KDM4ELMNAPKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485169-B2 Compounds Grey Wolf Therapeutics Limited (GB) 2025-12-02 US disclosed
US-20230064417-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2023-03-02 US disclosed
EP-3883650-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2021-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230064417-A1 COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 ALDH1A1 2613/4885KDM4E 2853/4885LMNA 2596/4885
US-12485169-B2 Compounds SLC10A1, VHL, CFTR ALDH1A1 276/4885KDM4E 4372/4885LMNA 2582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.